Navigation Links
USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R)
Date:3/10/2009

NEW YORK, March 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that the U.S. Patent and Trademark Office has issued a Notice of Final Determination granting the full five years of patent term extension for U.S. Patent No. 5,061,703 (the '703 Patent), which is listed in the U.S. Food and Drug Administration Orange Book for NAMENDA(R) (memantine hydrochloride). Forest has an exclusive license to the '703 patent from the German pharmaceutical company Merz Pharma. Forest and Merz have commenced patent litigation against several generic manufacturers who have filed ANDAs seeking FDA approval to market generic versions of NAMENDA. A trial in this litigation, pending in the U. S. District Court for the District of Delaware, is scheduled for April 2010. After review of the regulatory timeline for approval of NAMENDA(R) the U.S. Patent and Trademark Office determined that the '703 Patent is entitled to the full five years of patent term extension and will expire on April 11, 2015 instead of as originally anticipated on September 13, 2013.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Merz

Merz Pharmaceuticals researches, develops, produces and distributes innovative pharmaceutical products in the areas of neurology and psychiatry as well as in aesthetic dermatology and metabolism. In the area of Alzheimer's research, Merz Pharmaceuticals has achieved a leading position with the first active ingredient worldwide for the treatment of moderate to severe Alzheimer's disease. The company is headquartered in Frankfurt am Main, Germany. To learn more about Merz, visit www.merz.com.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. USPTO Issues Patent Embodying Methodologies for Abating a Broad Range of Allergens, Pathogens, Viruses, Bacteria, Odors and Volatile Organic Compounds.
2. USPTO Confirms Validity of Bystolic(R) Patent
3. Guru Program Pioneered by Tom Gable Receives Official Registration from USPTO
4. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
5. PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
7. American Red Cross Issues Blood Supply Alert
8. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
9. New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
10. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
11. Audio: New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: